期刊文献+

云克联合钙剂和维生素D3治疗类风湿关节炎骨质疏松的疗效观察 被引量:15

Efficacy of 99Tc-MDP combined with calcium and vitamin D3 for treating secondary osteoporosis in patients with rheumatoid arthritis
原文传递
导出
摘要 目的观察99Tc-亚甲基二膦酸盐(商品名:云克)联合钙剂和维生素D3对类风湿关节炎(RA)及RA骨质疏松的治疗效果。方法选取2015年1月至2016年12月间的50例RA骨质疏松患者作为观察组,其中男19例、女31例,平均年龄(56.21±18.32)岁,给予云克、钙剂和维生素D3治疗。选取39例RA骨质疏松患者作为对照组,给予甲氨蝶呤、钙剂和维生素D3治疗,其中男16例、女23例,平均年龄(60.37±12.56)岁。比较治疗前与治疗后(3、6、12个月) 2组患者RA症状及骨密度(BMD)改善情况等。采用两样本t检验分析数据。结果2组患者在治疗后3和6个月在改善晨僵、减少关节压痛及肿胀方面均有较好治疗效果,两者疗效差异无统计学意义(t值:0.3~0.6,均P〉0.05)。治疗后6个月,观察组患者L2~L4椎体与股骨颈BMD分别为(0.64±0.05)和(0.59±0.06) g/cm2,治疗后12个月分别为(0.81±0.04)和(0.79±0.06) g/cm2,均高于同期对照组相应BMD[(0.51±0.04)和(0.50±0.05)、(0.59±0.03)和(0.52±0.05) g/cm2;t值:8.3~9.9,均P〈0.05]。结论云克联合钙剂和维生素D3对RA引起的骨质疏松治疗效果明显。 ObjectiveTo observe the efficacy of 99Tc-methylene diphosphonate (MDP) combined with calcium and vitamin D3 in the treatment of rheumatoid arthritis (RA) and secondary osteoporosis.MethodsFifty patients (19 males, 31 females, average age: (56.21±18.32) years) with RA and secondary osteoporosis from January 2015 to December 2016 were selected as observation group. All of them were treated with 99Tc-MDP, calcium and vitamin D3. Another 39 patients with RA and secondary osteoporosis were randomly selected as control group, including 16 males and 23 females (average age: (60.37±12.56) years), and all were treated with methotrexate, calcium and vitamin D3. Curative effects before and after (3, 6, 12 months) the treatment were observed and compared. Two-sample t test was used for data analysis.ResultsBoth of the 2 groups showed good response, and there was no statistical significance in improvement of morning stiffness, reducing joint tenderness and swelling (t values: 0.3-0.6, all P〉0.05). The bone mineral density (BMD) of L2-L4 vertebral bodies and femoral neck were (0.64±0.05) and (0.59±0.06) g/cm2 6 months after treatment, and were (0.81±0.04) and (0.79±0.06) g/cm2 12 months after treatment in the observation group, which were all higher than those in the control group ((0.51±0.04), (0.50±0.05), (0.59±0.03), (0.52±0.05) g/cm2;t values: 8.3-9.9, all P〈0.05).Conclusion99Tc-MDP combined with calcium and vitamin D3 for RA and RA osteoporosis may achieve good curative effect.
作者 黄禾 陈跃 Huang He;Chert Yue(Department of Nuclear Medicine,the Affiliated Hospital of Southwest Medical University,Luzhou 646000,China)
出处 《中华核医学与分子影像杂志》 CAS 北大核心 2018年第9期615-618,共4页 Chinese Journal of Nuclear Medicine and Molecular Imaging
关键词 关节炎 类风湿 骨质疏松 胆骨化醇 99M锝美罗酸盐 治疗结果 Arthritis rheumatoid Osteoporosis Cholecalciferol Technetium Tc 99m medronate Treatment outcome
  • 相关文献

参考文献6

二级参考文献40

  • 1张宁.类风湿关节炎的治疗进展[J].实用药物与临床,2006,9(3):131-133. 被引量:15
  • 2黄烽,邓小虎,张江林,梁东风,郭军华,李胜光,朱剑,李晓峰.英利昔单抗联合甲氨蝶呤治疗类风湿关节炎的随机双盲临床研究[J].中华风湿病学杂志,2006,10(9):522-526. 被引量:15
  • 3艾脉兴,马丽,赵孟君,王丽英,林冰,王国春,吴东海.依那西普治疗活动性类风湿关节炎的安全性和有效性[J].中国新药杂志,2007,16(15):1208-1211. 被引量:12
  • 4张乃峥.类风湿关节炎[A].见:张乃峥主编.临床风湿病学[C].上海:上海科学技术出版社,1999.118—137.
  • 5张育,何斌,李国青,周玮,高娜,高波,顾健.沙利度胺联合甲氨蝶呤治疗类风湿性关节炎的疗效观察[J].中国医药,2007,2(11):641-642. 被引量:12
  • 6Redlich K, Hayer S, Maier A, et al. Tumor necrrosis factor alphamedialed joinl destruction is inhibited by targeting osteoclasts wilh osteoprotegerin. Arthrilis Rheum, 2002, 46: 785-792.
  • 7Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31:315-324.
  • 8Goldring SR, Gravallese EM. Mechanisms of bone loss inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res, 2000, 2: 33-37.
  • 9Haugeberg G, Orstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol, 2003, 15: 469-475.
  • 10Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastgensis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA, 1998, 95: 3597-3602.

共引文献3191

同被引文献96

引证文献15

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部